Dr Kara Perrow

VC’s Postdoctoral Research Fellow
Room: 32.229
Telephone: +61 2 4221 4256

kara@uow.edu.au

 

Research Interests

Development of ligand-directed targeted drugs for the treatment of malignant disease

Improved delivery platforms for chemotherapeutic drugs, including reformulation and the use of bio-responsive nanoparticles

Development of novel microtubule targeting drugs

Combination anti-cancer therapy and overcoming MDR mechanisms

Representative Publications

T.K. Stutchbury, K.L. Vine, J.M. Locke, J.S. Chrisp, J.B. Bremner, P.R. Clingan, M. Ranson (2011) Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles. Anticancer Drugs 22, 24-34.

K.L Vine, J.M. Locke, J.B. Bremner and M. Ranson Selective targeting of 2'-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro (2010) Bioorg Med Chem Lett 20, 2908-2911.

K.L. Vine, L. Matesic, J.M. Locke, M. Ranson, D. Skropeta (2009) Cytotoxic and anticancer activities of isatin and its derivatives: a comprehensive review from 2000-2008. Anticancer Agents Med Chem 9, 397-414.

B.J. Cochran, L.P. Gunawardhana, K.L. Vine, J.A. Lee, S. Lobov, M. Ranson (2009) The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity BMC Biotechnol 9, 43.

K.L. Vine, J.M. Locke, M. Ranson, S.G. Pyne and J.B. Bremner (2007) An investigation into the cytotoxicity and mode of action of some novel N-alkyl substituted isatins. J Med Chem 50, 5109-5117.  

Full publication list

Current Students

Vineesh Narayanan (PhD) Understanding HER2-uPAR receptor crosstalk and their role in tumour progression (Co-supervised with A.Prof Marie Ranson).

Andrew Hall (Biol392) Development and assessment of novel, targeted cytotoxin-loaded nanoparticles.

Luke Jones (BSc) Investigating the MOA and anticancer effect of a novel class of isatin molecules in combination therapy and in drug resistant cancers.

Clare Watson (BSc) Assessment of the anticoagulant and antiangiogenic properties of sulfated β-cyclodextrins in novel anticancer formulations incorporating 5-fluorouracil (Co-supervised with A.Prof Marie Ranson).

Emma Langshaw (Bio292) Characterising drug permeation through skin using a microemulsion based delivery vehicle (Co-supervised with Dr Jason McArthur).

Future Topics for Students

Functionalised liposomes for targeted drug delivery

Understanding the protective effect of PAI-2 in cancer

Abbreviated CV

2011- 2014 VC’s Postdoctoral Research Fellow, IHMRI, University of Wollongong, NSW, Australia.

2011 Visiting Postoctoral Fellow, Finsen Laboratory, Copenhagen Biocenter, Denmark.

2011 Visiting Postoctoral Fellow, University of Malmö, Sweden.

2010 Research Fellow, School of Biological Sciences, University of Wollongong, NSW, Australia (funded by Cure Cancer Australia Foundation and Cancer Australia).

2008-2009 Lecturer and Subject Coordinator, School of Biological Sciences, University of Wollongong, NSW, Australia.

2003-2007 PhD School of Biological Sciences, University of Wollongong ‘An investigation into the cytotoxic properties of isatin-derived compounds and potential for use in targeted cancer therapy’.